Skip to main content
YUNGJIN PHARM. CO., LTD logo

YUNGJIN PHARM. CO., LTD — Investor Relations & Filings

Ticker · 003520 ISIN · KR7003520004 KO Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2026-01-16 Earnings Release
Country KR South Korea
Listing KO 003520

About YUNGJIN PHARM. CO., LTD

https://eng.yungjin.co.kr/

Yungjin Pharm. Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products for domestic and international markets. The company's portfolio includes a range of prescription drugs, with a focus on areas such as cephalosporin antibiotics and antipsychotic medications. Yungjin Pharm is actively involved in advancing its R&D pipeline, which includes collaborative research for treatments of rare conditions like mitochondrial diseases. Leveraging extensive drug production expertise and R&D capabilities, the company operates as a key affiliate within the KT&G Group's bio/pharmaceutical business.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (Youngjin Pharm) announcing a significant change in financial structure (30% or more change in revenue or profit). This is a standard 'Earnings Release' (ER) type filing in the Korean market (DART system), providing preliminary financial results before the final audited report is published. It contains key financial highlights, comparative data, and reasons for the change, fitting the definition of an Earnings Release. FY 2025
2026-01-16 Korean
[기재정정]투자판단관련주요경영사항
Management Reports Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a 'Major Management Matter' (주요경영사항) related to a technology transfer agreement. It details changes in the counterparty of a licensing contract (assignment of rights). Since this is a specific regulatory disclosure regarding a material business event (contract amendment) and does not fit into categories like M&A (which usually implies corporate mergers/acquisitions) or other specific financial reports, it is classified as a general Regulatory Filing (RNS).
2025-12-22 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled as a preliminary (잠정) business performance announcement for 영진약품 covering the period from July 1, 2025 to September 30, 2025. It contains summarized financial figures such as sales, operating profit, and net income, but explicitly states these are provisional figures not yet audited or finalized. The document is short (2100 characters) and serves as a public disclosure of preliminary financial results ahead of a scheduled investor presentation. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory disclosure of preliminary earnings data, which fits the category of Earnings Release (ER) as it announces key financial highlights for a quarter. Therefore, the appropriate classification is Earnings Release (ER) with high confidence. Q3 2025
2025-11-05 Korean
[기재정정]단일판매ㆍ공급계약체결
Capital/Financing Update Classification · 95% confidence The document is a disclosure about a single sales and supply contract, including details about contract extension, contract amount, payment terms, and related parties. It is a regulatory announcement about a contract agreement and its amendment, not a financial report or earnings release. The document length is short (2275 characters) and it focuses on contract details rather than financial performance or management discussion. This fits the category of a Capital/Financing Update (CAP) as it relates to contract agreements impacting company operations and revenue streams.
2025-10-02 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Regulatory Filings Classification · 100% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Youngjin Pharm, a subsidiary of the KT&G corporate group. It provides specific regulatory disclosures regarding circular shareholding, voting rights of financial/insurance companies, and inter-company transactions as required by Korean fair trade regulations. Since it is a mandatory regulatory disclosure of corporate group status and does not fit into specific categories like financial reports or shareholder meeting materials, it is classified as a Regulatory Filing (RNS).
2025-08-28 Korean
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Yungjin Pharm. Co., Ltd. for the fiscal year 2024. It contains comprehensive financial statements, management discussion and analysis, governance information, and operational details. It is a formal, full-year regulatory filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). According to the provided definitions, this corresponds to the 10-K category. FY 2024
2025-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.